Zenlabs Ethica Limited is a **WHO-GMP certified** pharmaceutical company headquartered in Chandigarh, India. Operating as a key entity within the **Preet Remedies Group**, the company has transitioned from its historical roots in financial services to become a specialized marketing and trading powerhouse in the pharmaceutical sector. The company is listed on the **BSE Limited** and maintains a significant footprint in both domestic Indian markets and international territories, particularly in **Southeast Asia**. --- ### **Core Business Model & Specialized Product Portfolio** Zenlabs Ethica operates as a lean, marketing-driven entity. Its business model focuses on the distribution and supply chain management of branded pharmaceutical formulations, leveraging the manufacturing capabilities of its parent group and strategic international partners, such as **Zenlabs Pharmaceutical Inc, Canada**. The company manages a vast portfolio of over **600 products** across diverse therapeutic segments: | Category | Therapeutic Focus & Products | | :--- | :--- | | **Chronic Care** | **Anti-Diabetics** (blood sugar management) and **Anti-Hypertensive** drugs (cardiovascular health). | | **Acute Care** | **Gastrointestinal (GIT)** disorder medications, **Anti-Infectives**, and **Anti-Bacterial** drugs. | | **Specialized Medicine** | Recent expansions into **Neurology**, **Cytrics**, and oncology-related segments. | | **Consumer & Wellness** | Medicated **Soaps**, antimicrobial personal care products, and a robust line of **Nutraceuticals** (dietary supplements). | The company operates through three primary brand divisions: **Zenlabs**, **Coles Pharma**, and **Mega Star**. While the company maintains records for equipment, it follows an asset-light model, owning **no immovable property or intangible assets** as of March 2025. --- ### **Strategic Leadership & Corporate Governance** The company is currently in a "progressing mode," prioritizing leadership continuity to ensure long-term stability and the execution of its expansion strategy. **Key Management Appointments:** * **Mr. Sanjeev Kumar (Managing Director):** Re-appointed for a **5-year term** (Sept 1, 2024 – Aug 31, 2029). * **Mr. Sanjay Dhir (Whole Time Director):** Appointed for a **5-year term** (April 1, 2025 – March 31, 2030). **Governance Framework:** * **Compliance Standards:** Adheres to **Indian Accounting Standards (Ind AS)** and **SEBI (LODR) Regulations, 2015**. * **Audit Quality:** Consistently maintains an **unmodified (unqualified) audit opinion** (2023–2026). * **Transparency:** Utilizes **Remote e-voting** for shareholder meetings and employs independent scrutinizers (**M/s Jaspreet Dhawan & Associates**) to oversee corporate resolutions. --- ### **Financial Structure & Capital Management** Zenlabs Ethica maintains a lean capital structure, recently focused on "cleaning up" the balance sheet following historical merger activities. | Financial Metric | Value (as of March 31, 2025) | | :--- | :--- | | **Paid-up Capital** | **₹6,51,00,150** | | **Net Worth** | **₹10,42,50,150** | | **Working Capital Limit** | **> ₹5 Crores** | | **Cash & Bank Balances** | **₹1.62 Crores** (as of March 2023) | **Exceptional Items & Legacy Issues:** The company recently undertook a rigorous exercise to write off non-recoverable **Trade Receivables** (Bad Debts) that originated prior to the company’s merger process. While this led to an **"Emphasis of Matter"** in audit reports, it was deemed necessary for financial transparency. Some trade payables and advances remain subject to confirmation, though management expects no material impact from future reconciliations. --- ### **Regulatory Transition & Risk Profile** The company has navigated a significant structural shift following the **cancellation of its NBFC registration** by the **Reserve Bank of India (RBI)** on **November 7, 2025**. This led to a strategic realignment, including the disposal of non-core investments and a resulting exceptional loss of **₹2.08 crore** in early 2026. #### **Operational & Market Risks** * **Pricing Pressures:** Exposure to the **National List of Essential Medicines (NLEM)**. The 2022 price reductions on **384 drugs** across **27 categories** continue to impact margins. * **Market Competition:** High fragmentation in the Indian pharma market leads to intense price competition. * **Input Costs:** Rising operational expenses and volatile raw material costs. #### **Compliance & Legal Risks** * **Taxation:** Reported **₹6.79 Lakhs** in contingent liabilities related to **GST** litigations. In February 2026, the company received a demand notice under **Section 73** of the CGST Act. * **Governance Lapses:** Recent scrutiny regarding **SEBI Insider Trading (PIT) Regulations** and the delayed registration of two **Independent Directors** in the mandatory Databank. #### **Financial Risk Mitigation** The company employs a formal **Risk Management Policy** and a **Vigil Mechanism (Whistle Blower Policy)**. * **Credit Risk:** Mitigated by strictly dealing with creditworthy counterparties. * **Liquidity Risk:** Managed through unencumbered assets and consistent monitoring of cash flows. * **Actuarial Risk:** Management monitors discount rates and salary escalation factors affecting employee benefit obligations. --- ### **Future Outlook** Zenlabs Ethica is focused on optimizing its trading-centric business model by upscaling distribution capabilities and expanding its global footprint. By shedding its legacy financial services identity and doubling down on **branded formulations** and **nutraceuticals**, the company aims to capture emerging opportunities in the chronic care and wellness segments while navigating the complexities of Indian pharmaceutical regulations.